Guidelines for treatment of HIV infected adults in Europe
Retreatment of hepatitis C — sofosbuvir/velpatasvir/ voxilaprevir (SOF/VEL/VOX) 1
In the RESOLVE study, 77 patients with hepatitis C who had
previously failed direct acting antiviral therapy (DAA) were
treated with SOF/VEL/VOX for 12 weeks.
EACS Guidelines
Magazine